Ku ya 13 Kanama 2025, urubuga rwemewe rw’Inama Mpuzamahanga ku Kanseri y’Ibihaha yo mu 2025 (WCLC) rwashyize ahagaragara incamake z’ubushakashatsi bwatoranyijwe mu nama y’uyu mwaka, Imwe mu ngingo z’ingenzi harimo incamake nshya y’igerageza rya mbere rya HLX43, Henlius’ PD-L1 ADC.
Kugeza ubu, haracyari igeragezwa ryinshi ry’ikoranabuhanga rishya rirwanya kanseri mu Bushinwa rishaka abarwayi. Inama ku miti mishya n’ikoranabuhanga, ushobora kuvugana n’Ishami Mpuzamahanga ry’Ibitaro bya Oncology bya Beijing mu Karere k’Amajyepfo.
Nimero ya Terefone: 4008803716
Indangamuntu ya WeChat: 17801183037
Email：myimmnet@163.com
HLX43 ni umuti wa ADC urwanya kanseri ukoresheje imiterere myinshi, ukaba wibasira PD-L1, ugaragaza uburyo bubiri buhuza uburyo bwo gukumira indwara no guhumanya umubiri. Amakuru y’ibanze yagaragaje ko HLX43 ifite ingaruka nziza zo kurwanya kanseri kandi ikaba ishobora kwihanganira kanseri y’ibihaha itari nto (NSCLC), kanseri y’inkondo y’umura (CC), kanseri y’uturemangingo two mu ruhu (ESCC), n’izindi ndwara za kanseri zitari zikirindwa na PD-1/L1 mAb.
Dukurikije incamake ivuguruye, HLX43 ikomeje kugaragaza igipimo cyo hejuru cy’ubutabazi ku barwayi bafite ibibyimba bikomeye, cyane cyane ku barwayi ba NSCLC bavuwe mbere ariko bananiwe gukoresha imiti igabanya ubukana bw’indwara. HLX43 igaragaza imikorere myiza cyane mu matsinda runaka, aho igipimo cyo gusubiza neza (ORR) cya 47.4% muri NSCLC yo mu bwoko bwa EGFR wild-type non-squamous, mu gihe ikomeza kugira umutekano mwiza. Ikigaragara ni uko HLX43 igaragaza imikorere myiza hatitawe ku mikorere ya PD-L1, bigaragaza ubushobozi bwayo bwo kurwanya kanseri budafite aho bubogamiye.
Ifite akamaro mu kuvura indwara ya CPI-Resistant NSCLC: Kugeza ku ya 28 Gashyantare 2025, abarwayi 85 bahawe HLX43. Mu cyiciro cya Ia (kwiyongera k'umuti), abarwayi 21 bafite ibibyimba bikomeye bari bariyandikishije, mu gihe mu cyiciro cya Ib (kwiyongera k'umuti), abarwayi 64 ba NSCLC binjijwe mu matsinda atatu (2, 2.5, na 3 mg / kg). Ikigaragara ni uko 88.2% (75/85) by'abarwayi bananiwe uburyo bwo kuvura mbere (CPI).
Imikorere myiza muri NSCLC hamwe n'ibisubizo bifatika mu matsinda yihariye: Mu barwayi 76 ba NSCLC (69 bapimwe ku buryo bwo gukora neza), ORR yari 31.9% (22/69), hamwe n'igipimo cyo kurwanya indwara (DCR) cya 87.0% (60/69). Isesengura ry'amatsinda ryagaragaje ko HLX43 ifite akamaro gakomeye mu bantu runaka: amatsinda ya 2 mg/kg na 2.5 mg/kg muri Phase Ib yageze kuri ORR za 38.1% (8/21) na 33.3% (7/21), uko bikurikirana; abarwayi ba NSCLC batagira CPI (n=61) bagaragaje ORR ya 32.8% (20/61); abarwayi ba NSCLC bo mu bwoko bwa EGFR (n=19) bari bafite ORR ya 47.4% (9/19).
Imiterere myiza y’umutekano, imikorere myiza cyane hamwe n’uburozi buke: Mu cyiciro cya Ia, hagaragaye ikibazo kimwe cya DLT cyagaragaye mu itsinda rya 4 mg/kg. Ingaruka mbi zijyanye n’ubuvuzi (TRAEs) zagaragaye ku barwayi 95.2%, cyane cyane mu cyiciro cya 1-2. Ingaruka mbi za TRAEs zo mu cyiciro cya ≥3 zagaragaye ku barwayi 5 (23.8%), bose baturutse mu byiciro bya 3 na 4 mg/kg, akenshi umubare wa neutrophil wagabanuka (19%), umubare wa selile z’umweru (19.0%) na anemia (14.3%). Ingaruka mbi ziterwa n’ubudahangarwa bw’umubiri (irAEs) zavuzwe muri ubu bushakashatsi zigaragaza ko HLX43 ishobora gutera ingaruka ku buvuzi bw’umubiri. Ikigaragara ni uko abarwayi bagaragaje irAEs bagaragaje igipimo cyo hejuru cy’ubutabazi (ORR).
Ikora neza mu miterere itandukanye y’ibipimo by’isuzuma: Abarwayi ba NSCLC banduye PD-L1 (n=50) bagaragaje ORR ya 32.0% (16/50) mu gihe abarwayi ba PD-L1 badafite/batazwi (n=19) babonye ORR ya 31.6% (6/19), nta tandukaniro rigaragara ryagaragaye.
Kugeza ubu, haracyari igeragezwa ryinshi ry’ikoranabuhanga rishya rirwanya kanseri mu Bushinwa rishaka abarwayi. Inama ku miti mishya n’ikoranabuhanga, ushobora kuvugana n’Ishami Mpuzamahanga ry’Ibitaro bya Oncology bya Beijing mu Karere k’Amajyepfo.
Nimero ya Terefone: 4008803716
Indangamuntu ya WeChat: 17801183037
Email：myimmnet@163.com
Igihe cyo kohereza: Kanama-15-2025